The Technical Analyst
Decibel Therapeutics, [DBTX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Decibel Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
-0.81% $4.91
America/New_York / 22 sep 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 123.37 mill |
| EPS: | -2.54 |
| P/E: | -1.933 |
| Earnings Date: | Nov 06, 2023 |
| SharesOutstanding: | 25.13 mill |
| Avg Daily Volume: | 0.215 mill |
| RATING 2023-10-04 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.933 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.33x |
| Company: PE -1.933 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 4.77 - 5.05 ( +/- 2.91%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-09-25 | Trask Anna | Sell | 106 864 | Common Stock |
| 2023-09-25 | Trask Anna | Sell | 45 000 | Stock Option (right to buy) |
| 2023-09-25 | Trask Anna | Sell | 52 500 | Stock Option (right to buy) |
| 2023-09-25 | Trask Anna | Sell | 137 302 | Stock Option (right to buy) |
| 2023-09-25 | Carson William H. | Sell | 5 000 | Common Stock |
| INSIDER POWER |
|---|
| -72.09 |
| Last 92 transactions |
| Buy: 13 490 376 | Sell: 25 219 441 |
Forecast:
01:40 - $4.87
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $4.91 (-0.81% ) |
| Volume | 1.055 mill |
| Avg. Vol. | 0.215 mill |
| % of Avg. Vol | 491.47 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DBTX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DBTX
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Latest Press Releases
2023-09-05 11:21:00 - Press Release
Decibel Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Decibel Therapeutics, Inc. - Dbtx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of decibel therapeutics, inc. (nasdaqgs: dbtx) to regeneron pharmaceuticals, inc. (nasdaqgs: regn). under the terms of the proposed transaction, shareholders of decibel will receive only $4.00 in cash for each share of decibel that they own, with an additional non-tradeable contingent value right (cvr) to receive.
2023-08-12 12:45:00 - Press Release
Decibel Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, Llc Investigates Adequacy Of Price And Process In Proposed Sale Of Decibel Therapeutics, Inc. - Dbtx
New orleans--(business wire)--former attorney general of louisiana charles c. foti, jr., esq. and the law firm of kahn swick & foti, llc (“ksf”) are investigating the proposed sale of decibel therapeutics, inc. (nasdaqgs: dbtx) to regeneron pharmaceuticals, inc. (nasdaqgs: regn). under the terms of the proposed transaction, shareholders of decibel will receive only $4.00 in cash for each share of decibel that they own, with an additional non-tradeable contingent value right (cvr) to receive.
2023-08-11 07:45:00 - Press Release
Decibel Therapeutics Reports Second Quarter 2023 Financial Results And Corporate Update
- activated chord tm clinical trial sites in u.s., u.k. and spain and commenced patient screening activities; anticipate dosing first patient in the phase 1/2 clinical trial in the second half of 2023 -
2023-08-09 11:27:00 - Press Release
Shareholder Alert: Ademi Llp Investigates Whether Decibel Therapeutics, Inc. Has Obtained A Fair Price In Its Transaction With Regeneron
Milwaukee , aug. 9, 2023 /prnewswire/ -- ademi llp is investigating decibel (nasdaq: dbtx) for possible breaches of fiduciary duty and other violations of law in its transaction with regeneron. click here to learn how to join the action https://www.ademilaw.com/case/decibel-therapeutics-inc or call guri ademi toll-free at 866-264-3995.
2023-08-09 10:22:00 - Press Release
Dbtx Stock Alert: Halper Sadeh Llc Is Investigating Whether The Sale Of Decibel Therapeutics, Inc. Is Fair To Shareholders
New york--(business wire)--halper sadeh llc, an investor rights law firm, is investigating whether the sale of decibel therapeutics, inc. (nasdaq: dbtx) to regeneron pharmaceuticals, inc. is fair to decibel shareholders. under the merger, decibel shareholders will receive $4.00 per share in cash and a non-tradeable contingent value right entitling such holders to receive up to $3.50 per share in cash if certain clinical development and regulatory milestones are achieved. halper sadeh encourages.
Latest News
2023-09-15 18:32:23 - Seeking Alpha
Decibel Therapeutics' CVR Appears Around Fair Value
Decibel Therapeutics is being acquired by Regeneron for a cash consideration of $4/share and a CVR linked to DB-OTO. DB-OTO is a gene therapy for hearing loss, with a phase 1/2 trial underway. The CVR broadly pays out with the early stages of the Phase III trial and subsequently the filing of a BLA application (or European equivalent).
2023-08-09 12:35:33 - Investopedia
Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals
Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene therapy pipeline.
2023-08-09 10:00:22 - InvestorPlace
Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal
Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This deal has Regeneron Pharmaceuticals agreeing to acquire Decibel Therapeutics for $4 per share in cash.
2023-08-09 09:43:50 - Proactive Investors
Decibel Therapeutics shoots up 72% on Regeneron bid
Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be a knock-out bid for the tiny drug developer. The deal values Decibel Therapeutics, which is working on treatments aimed at enhancing and restoring hearing and balance, at $109 million.
2023-08-09 07:55:00 - Market Watch
Regeneron buying small cap Decibel Therapeutics for $4 a share
Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its closing price of $2.79 a share in the previous session. Boston-based Decibel Therapeutics is a clinical-stage biotechnology company with a focus on discovering and developing transformative treatments to restore and improve hearing and balance.
2023-06-01 16:30:00 - GlobeNewsWire
Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy
2023-05-10 16:30:00 - GlobeNewsWire
Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held in Los Angeles, California May 16 – 20th, 2023.
2023-02-09 07:00:00 - GlobeNewsWire
Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting
BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.
2022-08-31 07:00:00 - GlobeNewsWire
Decibel Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September.
2022-06-29 13:28:34 - PennyStocks
Top Penny Stocks Today? 3 You Might Want To Watch Before Next Week
